UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.

doi:10.1136/jmg-2022-108898

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.

Journal of medical genetics - 1 May 2023

Hanson Helen, Kulkarni Anjana, Loong Lucy, Kavanaugh Grace, Torr Bethany, Allen Sophie, Ahmed Munaza, Antoniou Antonis C, Cleaver Ruth, Dabir Tabib, Evans D Gareth, Golightly Ellen, Jewell Rosalyn, Kohut Kelly, Manchanda Ranjit, Murray Alex, Murray Jennie, Ong Kai-Ren, Rosenthal Adam N, Woodward Emma Roisin, Eccles Diana M, Turnbull Clare, Tischkowitz Marc, Lalloo Fiona

Abstract excerpt

Germline pathogenic variants (GPVs) in the cancer predisposition genes BRCA1, BRCA2, MLH1, MSH2, MSH6, BRIP1, PALB2, RAD51D and RAD51C are identified in approximately 15% of patients with ovarian cancer (OC). While there are clear guidelines around clinical management of cancer risk in patients with GPV in BRCA1, BRCA2, MLH1, MSH2 and MSH6, there are few guidelines on how to manage the more moderate OC risk in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Consensus

Share to Fanconi Anemia Complementation Group N Protein

Share to Germ Cells

Share to Germ-Line Mutation

Share to MutS Homolog 2 Protein

Share to Ovarian Neoplasms

Share to United Kingdom

Source

Open in PubMed Open full text

Identifiers

PMID: 36411032
DOI: 10.1136/jmg-2022-108898
PMCID: PMC10176381

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.PMID 36411032Read ↗

Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).Semantic proximity Read ↗

Pathogenic Variants in BRIP1, RAD51C, and RAD51D Identified with Multi-Gene Panel Testing for Hereditary CancersSemantic proximity Read ↗

Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes.Semantic proximity Read ↗

Rare Germline Genetic Variants and the Risks of Epithelial Ovarian CancerSemantic proximity Read ↗

What About the Others? Clinical Management of Gynecologic Cancer Risk in Patients With Moderate-Risk Hereditary Cancer Genes ( ATM , BRIP1 , RAD51C , RAD51D , and PALB2 ).Semantic proximity Read ↗

A decade of RAD51C/D: Germline pathogenic variants and their phenotypic landscapeSemantic proximity Read ↗

Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC).Semantic proximity Read ↗

Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes.Semantic proximity Read ↗

Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.Semantic proximity Read ↗

BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.Semantic proximity Read ↗

Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?Semantic proximity Read ↗

A decade of RAD51C and RAD51D germline variants in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.